Should you buy Immunitybio stock now?
Yes, the technical signal for Immunitybio is currently Strong Buy. Immunitybio trades at $9.69 as of Oct 7, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 0.490 with rising momentum (signal: 0.345); RSI is at 60.6 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $12.75 points to 31.6% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Immunitybio stock?
The average analyst price target for Immunitybio is $12.75. The current price is $9.69, which gives an upside of 31.6%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $11.48 and $14.03.
Is Immunitybio a dividend stock?
No, Immunitybio does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Immunitybio stock?
Immunitybio is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 106.0%, which classifies the stock as Extremely speculative.
Is Immunitybio overvalued?
No, Immunitybio is considered undervalued based on the analyst price target (31.6% upside). Immunitybio has the following valuation ratios: a P/S ratio of 59.3. The analyst price target suggests that the stock is undervalued by 31.6%.
Is Immunitybio overbought?
No, Immunitybio is not overbought. RSI is at 60.6 (neutral zone). The technical indicators show: RSI is at 60.6 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 10.8% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Immunitybio earnings report?
Immunitybio reports its next earnings on November 3, 2026. The stock currently trades at $9.69.
Is Immunitybio shorted?
Yes, Immunitybio is shorted with 31.3% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Immunitybio stock?
No, insiders are not buying Immunitybio shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 2 sales. On a net basis, 856,530 $ worth of shares were sold. Across the last 20 reported transactions, the split is 4 purchases and 16 sales, with a net 6,392,335 $ sold. Active sellers include Simon Barry J., Cohen Cheryl, Selecky Christobel. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Immunitybio a good stock?
Based on our total score, Immunitybio is rated as a poor stock with a total score of 31 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 2/100, Quality: 12/100, Momentum: 79/100. In addition: analysts see 31.6% upside to the price target; technical signal: Strong Buy. Whether Immunitybio is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Immunitybio stock?
The outlook for Immunitybio based on current data: the average analyst price target is $12.75 (+31.6%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Nov 3, 2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Immunitybio stock rising?
Immunitybio is rising right now. The technical indicators show: the price is 10.8% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 31.3% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Immunitybio go?
The average analyst price target for Immunitybio is $12.75, which corresponds to a potential gain of 31.6% from the current price of $9.69. The stock has traded between $1.95 and $12.43 over the last 52 weeks. The price is 22.0% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Immunitybio fall?
The stock has traded as low as $1.95 over the last 52 weeks — that is 79.9% below the current price of $9.69. The biggest decline (drawdown) in the same period was 84.3% from high to low. Within a year, the price typically swings about ±106.0% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Immunitybio do?
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the deve... The company belongs to the Healthcare sector, more specifically the Biotechnology industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Immunitybio as an investment.
Did Immunitybio raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Immunitybio. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Immunitybio making money or losing money?
We have no current profitability data for Immunitybio. See the latest report in the earnings history above.
Can Immunitybio go bankrupt?
The bankruptcy risk of Immunitybio is rated as elevated. Altman Z2 (a model for assessing financial distress) is -30.40 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Immunitybio have a lot of debt?
Yes, Immunitybio has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
